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Abstract  
Purpose: γ-H2AX, a DNA double strand break marker, was used to evaluate suramin 
sensitization effect in cisplatin-treated Capan-1-bearing mice xenografts. 
Methods: Mice bearing pancreatic cancer Capan-1 subcutaneous xenografts were treated 
with control vehicle, cisplatin (7.5mg/kg), suramin (10mg/kg) combined with cisplatin, or 
suramin (100mg/kg) combined with cisplatin. Tumor samples were taken on 45th day 
after initiation of treatment. DNA damage after drug treatment was evaluated using 
immunohistochemical staining with γ -H2AX antibody.  
Results: In terms of tumor growth, suramin at low dose enhanced tumor size shrinkage 
and delayed tumor regrowth compared to cisplatin alone, while high dose suramin 
antagonized cisplatin effect. Low dose suramin induced more DNA damage indicated by 
γ-H2AX positive staining; it is not significantly different from the cisplatin group though. 
 Conclusions: Present study identified the sensitization effect of low dose suramin on 
cisplatin-treated pancreatic cancer Capan-1 xenografts by inducing more tumor shrinkage 
and prolonged tumor regrowth delay. In addition, low dose suramin caused more DNA 
damage retaining indicated by higher level of γ-H2AX positive cells. This result serves as 
a preliminary study to use γ-H2AX as a DNA damage repair marker to evaluate suramin 
sensitization effect in DNA damaging agents 
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 Introduction 
Pancreatic cancer is a malignant tumor within the pancreatic gland. Pancreatic cancer is 
the 4th leading cause of cancer death for both men and women. Pancreatic cancer has 
been called a "silent" disease because in early stage pancreatic cancer usually does not 
cause symptoms. Cancer of the pancreas is curable only when it is found in its earliest 
stages, before metastasis appears. Patients have a poor prognosis in part because the 
disease is often locally advanced or metastatic at the time of diagnosis. The median 
survival time is less than 6 months. Pancreatic cancer is treated with surgery, radiation 
therapy, or chemotherapy. Researchers are also studying biological therapy to see 
whether it can be helpful in treating this disease. (4, 5, 6) 
 It has been known that Cisplatin is capable of causing DNA damage, and thus used in 
treatment of pancreatic cancer. Suramin has shown to act as a sensitizer to radiotherapy 
and chemotherapy at low dose (10-50µM). We carried out our experiment to find out 
whether suramin shows any sensitization effect on cisplatin treatment in pancreatic 
cancer. Cisplatin causes DNA damage by cross linkage usually at N-7 site of Guanine 
base. This results in DNA replication arrest and cell death if crosslink is not repaired. 
BRAC-2 is a gene that plays an important role in DNA break repair, but the cell line 
CaPan-1, which we have used is BRAC-2 deficient. Germline mutation in BRAC2 gene 
leads to the development of many other cancers such as Breast and Ovarian cancer along 
with Pancreatic Cancer. BRAC2 is human gene which is involved in repair of 
chromosome damage. (1, 3). Hence repair of DNA could not be assisted efficiently. In 
order to detect Double strand break in DNA, we used γ -H2AX as a double strand break 
marker.  γ -H2AX by itself cannot repair the damage, but it acts as a recruiter, and 
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collects other repairing proteins to the localization where damage happens and completes 
the repair. After DNA damage is repaired, γ-H2AX experience degradation by 
phosphotases. Based on this knowledge we hypothesize that γ-H2AX can be used as a 
DNA damage marker to evaluate the cisplatin effect and further to evaluate the suramin 
sensitization effect on cisplatin. In current study, immunohistochemical staining was 
conducted using anti- γ-H2AX antibody to visualize the cells experiencing DNA damage, 
and the percentage of damaged cells in different groups was compared.   (1,3)  
Method 
Cell Line  
Capan-1 cell was purchased from ATCC. It is a hypo-triploid cell line derived from liver 
metastasis of a pancreatic cancer patient with a germline mutation in BRAC2. Tumor 
cells were maintained as monolayer culture at 370C in a  humidified atmosphere 
containing 5% CO2 in IMDM (Iscove's Modified Dulbecco's Medium) supplemented 
with 20% FBS, 4 mM L-glutamine, 90ug/ml gentamycin, and 90 ug/ml cefotaxime. 
Chemicals and materials 
γ-H2AX antibody was purchased from cell signaling technology. Kits of LSAB2 system-
HRP and liquid DAB were purchased from DakoCytomation. 
Animal and drug treatment protocols 
Female athymic nu/nu mice (5-6 weeks old) had free access to sterilized rodent food and 
water ad libitum. Capan-1 cells (2 millioncells suspend in 100µl in a 1:1 solution of 
Matrigel and normal saline) were subcutaneously injected into bilateral sides of mice, and 
after 2 weeks, mice were randomized into 4 groups according to initial size. Cisplatin and 
suramin were dissolved in normal saline. Animals were treated with a single dose of 
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control vehicle, cisplatin (7.5 mg/kg), cisplatin + suramin (10 mg/kg) pretreatment, or 
cisplatin + suramin (100mg/kg) pretreatment at day 0. Cisplatin was given as single dose 
via i.v. injection, and suramin was given one day before the cisplatin treatment via i.p. 
injection. One month after the 1st cycle of treatment, the animals got the second cycle.  
The treatment schedule is the same as in the 1st cycle. Cisplatin (7.5 mg/kg) was given as 
single intravenous dose. Low dose suramin (10 mg/kg), or high dose suramin (100mg/kg) 
was given via i.p. injection a day before the cisplatin treatment. 10 days after the 2nd 
cycle of treatment, animals were anesthetized and tumor samples were harvested. Tumors 
were fixed, dehydrated, embedded in paraffin wax, cut to 5µm-thick sections, and stained 
for γ-H2AX. 
Immunostaining 
Immunostaining is a technique in which an antibody is used to link a cellular antigen 
specifically to a stain that can be more readily seen with a microscope. In our experiment 
γ-H2AX is an antigen in carcinoma and antibody is anti-γ-H2AX. Factors considered in 
designing our experiments include specimen source, antigen antibody affinity, antibody 
type, and detection enhancement methods. (2) 
Fixatives Specimen (slide) preparation involves fixatives. They stabilize tissue thereby 
protecting them from the rigors of subsequent processing and staining techniques. We 
used Formalin as a fixative in our experiment. Fixation strengths and times were 
optimized so that antigens and cellular structures were retained and epitope masking 
could be reduced to minimal. (2) 
Paraffin Sections Next we embed tissue in paraffin wax as it hardens tissue and provides 
excellent morphological detail and resolution. Because of their superior fidelity, clarity, 
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and preservational properties paraffin–embedded tissues have become the ultimate 
standard of immunohistochemistry in histology, and anytime where archiving of 
immunohistochemical information is required. (2) 
Antigen Retrieval Antigen retrieval is one of the most important steps in immunostaining 
technique. Antigen Retrieval involves application of heat for varying lengths of time to 
paraffin-embed tissue sections in sodium citrate buffer. During this procedure the energy 
provided helps break some of the bonds formed during fixation, thus increasing the 
number of positive cells available, and intensity of reactions, although the exact 
mechanism is unclear. Therefore 
antigen retrieval is done to 
maximize the availability of the 
antigen for interaction with a 
specific antibody. After a set 
time, the solution containing the 
slides is allowed to cool to room 
temperature slowly, and then 
slides are rinsed in PBS and used 
for staining. (2) 
Antibody Staining Further we used a procedure similar to standardized BrDU staining 
procedure. The proper working dilution for antibody was optimized. Dilution for our 
primary antibody anti-γ-H2AX was tested using 1:100 1:200, 1:400, and 1:800 dilution 
factors. The optimal antibody dilution is the one, which gives strongest specific antigen 
staining with the lowest non-specific background. In our experiment we got 1:400 as our 
 
 
Figure 1 immunohistochemical staining protocol 
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optimal antibody dilution. Biotinylated linker antibody solution (Yellow, containing anti-
mouse immunoglobulins) and peroxidase-labelled streptoavidin solution (Pink) forms a 
conjugation along with the primary antibody. Staining is completed after incubation with 
substrate DAB-chromosome, which results in a brown colored precipitate at the antigen 
site. (2). 
Enzyme-mediated Antibody Detection: When choosing a substrate for conversion by an 
enzyme, one should select a substrate, which yields a precipitating product. Enzyme 
involved in our experiment is HRP (Horseradish Peroxidase). HRP is specifically used  
for coloring thin slices of tissue biopsies for patients suspected to cancer. DAB (3, 3’-
Diaminobenzidine) is the substrate used in our experiment which produces brown end 
product and is highly insoluble in alcohol and other organic solvents.  
Cell Counting 
We used Optimas microscopy to take pictures and to count cells. Percentage of γ-H2AX 
positive cells was determined as follows: Number of brown (antibody-bound) cells 
divided by sum of Brown and Blue cells, times 100.  Blue colored cells are considered 
negative cells. Slides were counterstained with hematoxylin solution, thus contrast 
produced by blue colored cells benefited in identification of positive brown colored cells 
and in percentage counting of positive cells. (2)    
 Results 
Suramin enhanced tumor shrinkage after combined with cisplatin treatment 
After the 1st cycle of treatment, cisplatin alone suppressed tumor growth for about 7 days 
after the treatment, while addition of low dose suramin (10mg/kg) resulted in growth 
suppression for 11 days. At the 11th day, the average tumor sizes of these two groups 
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were 125% and 108% of the initial values, respectively. High dose suramin (100mg/kg) 
didn’t cause shrinkage of the tumor size or delay tumor growth compared to cisplatin 
alone treatment. The treatment of the 2nd cycle delayed the tumor progression for less 
than 1 week, and animals in all 3 groups started regrowing 1 week after the treatment. 
Addition of low dose suramin didn’t further prolong the tumor suppression duration. 
High dose suramin still showed obvious antagonistic effect. 
Suramin might have delayed DNA damage repair after treatment 
The presentative pictures of each group were shown in Figure 3 and red circles indicated 
the γ-H2AX positive cells, which suggested that the cells were damaged after drug 
treatment and the damage was not repaired at the time of anesthetization. 
The percentage of γ-H2AX positive cells was summarized in Table 1 and plotted in 
Figure 4 as bar graphs. The results showed that the groups of cisplatin, 
Suramin10+Cisplatin and Suramin100+Cisplatin had significant higher number of 
positive stained cells compared to Control. Suramin10+cisplatin had higher γ-H2AX 
positive cells than cisplatin alone and suramin100+cisplatin groups, but the difference is 
not statistically significant (p values are shown in Table 2).  
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Figure 2 Tumor growth curve after treatment 
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Figure 3. Representative γ-H2AX staining pictures in each groups 
Table 1. Percentage of γ-H2AX positive stained cells in each group 
 
 Control  Cisplatin Suramin10 + 
Cisplatin 
Suramin100 + 
Cisplatin 
Positive Stained Cells (%) 1.10 3.21 4.65 3.45 
Standard Deviation (±) 0.49 1.89 2.72 1.71 
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Figure 4. Graphical representation of  
γ-H2AX positive cells. 
Cntrl: control 
Cis: cisplatin 
S10C: suramin 10 + cisplatin 
S100C: suramin 100 + cisplatin 
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Table 2. summary of p-values 
 
 Cis Vs. Ctl S10C Vs. Ctl S100 Vs. Ctl S10C Vs. Cis S100C Vs. Cis 
P- value 0.010054 0.009182 0.012898 0.207561 0.423794 
 
Conclusion 
Present study identified the sensitization effect of low dose suramin on cisplatin-treated 
pancreatic cancer Capan-1 xenografts by inducing more tumor shrinkage and prolonged 
tumor regrowth delay. In addition, low dose suramin caused more DNA damage retaining 
indicated by higher level of γ-H2AX positive cells. This result serves as a preliminary 
study to use γ-H2AX as a DNA damage repair marker to evaluate suramin sensitization 
effect in DNA damaging agents. 
Discussion 
Our  study tested the feasibility of using γ-H2AX, the DNA double strand break marker, 
as an Pharmacodynamic endpoint to evaluate suramin sensitization effect. Low dose 
suramin did cause more unrepaired damage compared to cisplatin alone, but the 
difference is not statistically significant. The possible reasons might include the following:  
1) Limitation of sample size. As shown in figure 4, we got big variation for data set, 
which is due to heterogeneity of animal tumor samples. To decrease standard deviation, 
we could increase the number of observations by taking and counting more randomly 
selected pictures for each sample. 
2) in vivo experiment setting. γ-H2AX was reported to peak 24 hours after radiation 
treatment (7), and start to be degraded after that. So we can think that activation of γ-
H2AX is a fairly early effect after DNA damage, and once the damage is repaired 
                                                                                                                                  Patel                                                                   
 
11
sufficiently, the level of γ-H2AX will drop. In current experiment, the tumor samples 
were got after 2 cycles of treatments. As shown in Figure 1, tumors had regrown to fairly 
large sizes after the 1st cycle treatment, and the 2nd cycle of treatment didn’t cause as 
much tumor shrinkage as the 1st cycle did, possibly due to the acquired resistance, It is 
highly possible that the damage caused by 1st cycle treatment had been repaired, while 
the 2nd cycle didn’t cause much damage due to resistance. That could explain why the 
percentage of damaged cells was less than 5% in all groups, and the difference between 
groups was too small to be significant. Further study with earlier sampling time is 
expected to give a more clear result.  
The current study provides preliminary data to test the hypothesis that γ-H2AX can be 
used as a DNA damage marker to evaluate suramin sensitization effect in cisplatin treated 
pancreatic capan-1 xenografts. Further study is needed to support the hypothesis. 
 
Awareness 
• November is Pancreatic Cancer Awareness Month  
• Purple is the traditional color chosen to represent pancreatic cancer awareness.  
• Research spending per pancreatic cancer patient is $1145, the second lowest of 
any leading cancer. 
• The Pancreatic Cancer Action Network (PanCAN) was created as an advocacy 
group for pancreatic cancer.  
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